|
ABT-806 derived antibody drug conjugates (ADCs) inhibit growth of malignant mesothelioma in-vivo. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AbbVie; MSD |
Speakers' Bureau - Eisai; Merck Serono; Merck Serono |
Research Funding - AbbVie |
|
|
|
Research Funding - Abbvie |
Patents, Royalties, Other Intellectual Property - Abbvie |
Travel, Accommodations, Expenses - Abbvie |
|
|
|
Research Funding - Abbvie |
Patents, Royalties, Other Intellectual Property - Abbvie |
Travel, Accommodations, Expenses - Abbvie |
|
|
No Relationships to Disclose |
|
|
|
|
Consulting or Advisory Role - Abbvie |
Speakers' Bureau - Abbvie |
Research Funding - Abbvie |
Patents, Royalties, Other Intellectual Property - Abbvie |
Travel, Accommodations, Expenses - Abbvie |